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Abstract
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The purpose of this work was to compare the risk of developing a second cancer after craniospinal
irradiation using photon versus proton radiotherapy by means of simulation studies designed to
account for the effects of neutron exposures. Craniospinal irradiation of a male phantom was
calculated for passively-scattered and scanned-beam proton treatment units. Organ doses were
estimated from treatment plans; for the proton treatments, the amount of stray radiation was
calculated separately using the Monte Carlo method. The organ doses were converted to risk of
cancer incidence using a standard formalism developed for radiation protection purposes. The total
lifetime risk of second cancer due exclusively to stray radiation was 1.5% for the passively
scattered treatment versus 0.8% for the scanned proton beam treatment. Taking into account the
therapeutic and stray radiation fields, the risk of second cancer from intensity-modulated radiation
therapy and conventional radiotherapy photon treatments were 7 and 12 times higher than the risk
associated with scanned-beam proton therapy, respectively, and 6 and 11 times higher than with
passively scattered proton therapy, respectively. Simulations revealed that both passively scattered
and scanned-beam proton therapies confer significantly lower risks of second cancers than 6MV
conventional and intensity-modulated photon therapies.

1. Introduction
Recent advances in cancer detection and treatment have led to large improvements in
survival. The 10 year survival rates in the United States are approximately 59% for adults
and 75% in children (Ries et al 2006). Many believe that survival rates and quality of life
can be further improved by using more targeted treatments such as proton radiotherapy
(Steinberg et al 1990, McAllister et al 1997, Miralbell et al 2002, Suit 2003, Taylor 2003,
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Lee et al 2005, Yock et al 2005). If rates of long-term survival are increased, then so is the
importance of minimizing consequential treatment-related late effects that may appear years
or even decades after the treatment (see figure 1 in Preston et al (2002) and Sigurdson et al
(2005)). In particular, survivors of childhood cancer face the prospect of developing second
cancers later in life, with potentially devastating physical and psychological consequences. It
has long been known that radiation increases the risk of second cancers and that children are
at greater risk than adults. Consequently, much effort has been expended to develop
strategies that reduce exposures to healthy tissues, including the use of intensity-modulated
photon radiotherapy (IMRT) and proton therapy.
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Proton therapy is a scarce but rapidly emerging treatment modality (Sisterson 2005). In the
United States, five major proton therapy centers are presently in operation, and at least six
more are expected to commence treating cancer patients, including children, in the next 5
years. Much of the rationale for using proton therapy is based on theoretical considerations,
such as treatment planning studies, and on a limited number of patient outcome studies.
Skeptics argue that the proliferation of proton therapy should be contingent on the
availability of demonstrable benefit, e.g. from multi-institution randomized clinical trials
comparing survival rates after proton versus photon therapies. Proponents, however, argue
that waiting for clinical trial data would only confirm the obvious while slowing the pace of
progress. As a practical matter, it appears that many new proton therapy centers will begin
treating patients before the results of clinical trials are available. In the interim, we must rely
on theoretical predictions of expected benefits and detriments, and these predictions should
be as accurate and complete as reasonably achievable.
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Perhaps the most difficult detriment to predict is the risk of developing radiogenic second
cancer. This risk is common to all forms of radiotherapy, and the risks are usually
overwhelmed by the benefit of surviving the original cancer. In a recent study on pediatric
cancer treatments, Miralbell et al (2002) calculated that the risk of developing a second
cancer after craniospinal irradiation is substantially lower with proton therapy. Specifically,
they reported that the second cancer risk associated with scanned-beam protons was 8 times
less than with IMRT and 15 times less than with conventional radiotherapy. However, that
study did not take into account the cancer risks associated with stray neutron exposures,
which are inherent with proton therapy. Hall (2006) has cautioned that the neutron
exposures may be a predominant consideration in deciding whether proton therapy is
appropriate, particularly when contemplating the use of passively scattered beams to treat
children.
The aim of this work was to compare the risk of developing a second cancer after
craniospinal radiation using 6 MV conventional photon therapy, 6 MV intensity-modulated
photon therapy and proton radiotherapy taking into account neutron exposures from the
latter. In addition, we sought to compare the neutron exposures resulting from the two most
common proton beam spreading techniques, passive scattering and magnetic scanning. To
accomplish these goals, we combined dosimetric data from Monte Carlo simulations with
cancer risk coefficients from the literature.
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We investigated how whole-body stray neutron exposures influence the projected risk that a
patient receiving craniospinal proton irradiation will develop a second cancer. Stray
radiation doses were calculated using Monte Carlo simulations of a proton therapy treatment
unit with a detailed anthropomorphic phantom. Doses from the primary beam were taken
from the literature. The doses from primary and stray radiation were combined in order to
estimate the total attributable risk of the development of a fatal or non-fatal second cancer.
2.1. Calculation of absorbed dose, radiation weighting factor, equivalent dose and
effective dose
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In patients receiving proton therapy, the in-field (primary) dose is predominated by primary
protons and the out-of-field dose is predominated by neutrons (Agosteo et al 1998, Yan et al
2002, Fontenot et al 2008, Taddei et al 2008). For organs that are partially inside the
treatment field, the relative contribution of protons and neutrons depends mainly on the
fraction of the organ inside the treatment field. In this work, we report new calculations of
the out-of-field doses of stray radiation and then combine these with previously reported infield doses, in order to estimate the risk of second cancer from both in-field and out-of-field
radiation.
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Neutron radiation exposures were calculated with the Monte Carlo Proton Radiotherapy
Treatment Planning (MCPRTP) code (Newhauser et al 2007a). The MCPRTP system uses
the Monte Carlo N-particle eXtended code (MCNPX 2002(b), Hendricks et al 2006) as a
radiation dose calculation engine and a commercial proton treatment planning system
(Eclipse; Varian Medical Systems, Palo Alto, CA) for all other treatment-planning tasks.
The Monte Carlo simulations included realistic models for ion energy loss and energy
straggling, multiple Coulomb scattering and elastic and non-elastic nuclear reactions. The
MCPRTP system was described in detail elsewhere (Newhauser et al 2007a, 2008). A
pediatric medulloblastoma treatment was examined because children are more susceptible to
radiogenic cancers than adults, the expected survival time is long (for example, Stavrou et al
(2001) reported 52% survival at 10 yr), and the relatively large neutron exposures expected
from the deeply penetrating cranial fields and elongated spinal fields (Zheng et al 2007a).
The medulloblastoma treatment was simulated based on a simplified version of standard
craniospinal proton irradiation (St Clair et al 2004). In our study, the treatment technique
comprised four fields, including inferior and superior spinal fields delivered in the posterior–
anterior (PA) direction, and symmetric right and left cranial fields delivered in the posterior–
oblique direction (denoted as RPO and LPO). The prescribed absorbed dose (D) to the entire
target volume was 36 Gy, which was consistent with the prescribed dose in the study by
Miralbell et al (2002). There were, however, two noteworthy differences in our method
relative to theirs: patient size and organs size of the target volume. Miralbell et al considered
a 3 yr old boy whose treatment included only the spinal axis. In our study, the stray radiation
exposures to this boy were estimated from calculations for an adult male where the
treatment included irradiation of both the spinal axis and cranium. The impact of these
differences is discussed later. The water-equivalent range, water-equivalent spread-out
Bragg peak (SOBP) width and field sizes for the treatment fields used in the dose
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calculations were as follows: cranial field (12 cm range, 12 cm SOBP width and 208 cm2
area), superior spinal field (8 cm range, 8 cm SOBP width and 150 cm2 area), inferior spinal
field (8 cm range, 8 cm SOBP width and 144 cm2 area). Lastly, a complete craniospinal
irradiation usually includes a boost field to the posterior fossa. The boost field was excluded
for simplicity in this study; its proportion of the stray radiation exposure was small (Taddei
et al 2009).
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The stray radiation exposures associated with proton CSI was assessed with Monte Carlo
simulations that included the treatment unit and a stylized male phantom, as shown in figure
1. A stylized phantom was selected because of it allows greater reduced simulations times
compared to a comparable voxelized phantom. We used the Computerized Anatomical Man
(CAM) phantom, which is an anatomically realistic male phantom that was developed by
Billings and Yucker (Billings and Yucker 1973) for dose assessments in manned spaceflight,
comprises 2531 discretely defined geometric cells. The CAM model was converted for use
with MCNPX in a previous work (Fontenot et al 2008). CAM was also enhanced to utilize
more detailed and accurate information on the elemental compositions and mass density of
various tissues and organs. Specifically, we assigned six materials (organ tissue, skeletal
muscle, compact bone, bone marrow, skeletal bone and air) and six mass densities based on
data taken from Woodard and White (1986). Another enhancement was the addition of
strategically placed 2 cm diameter spherical receptors in various tissues and organs (e.g.
bladder, rectum, colon, lungs, stomach, liver, esophagus and thyroid). These spherical tallies
provided a relatively simple and computationally efficient means to simultaneously tally the
absorbed dose and neutron spectral fluence in a wide variety of locations throughout the
body. Equivalent dose to the remaining organs at risk (bone marrow, skin, bone surface and
remainder) was taken as the average equivalent dose over all explicitly defined organs. The
properties of the treatment fields, e.g. range, modulation width and field size, were selected
to provide a realistic and representative dose distribution in the phantom. For simplicity, the
RPO and LPO cranial fields were replaced with a single posterior field. The proton fields
incident on the phantom were used only to generate the stray radiation exposures; the doses
from the therapeutic proton radiation were taken from Miralbell et al (2002). The accuracy
of three-dimensional Monte Carlo dose predictions in heterogeneous phantoms was verified
previously (Titt et al 2008). Heterogeneity corrections, which are still common in photon
therapy dose calculations, were not applied since both the methods from Mirallbell et al for
predicting therapeutic dose and our methods for predicting stray radiation dose included
explicit modeling of the heterogeneities in the patient or phantom.
We simulated neutron exposures for the double scattering nozzle used at our institution as
well as for an idealized scanning nozzle (Newhauser et al 2008). The nozzles and radiation
transport were simulated using the MCNPX code, which was previously benchmarked for
proton therapy applications (Fontenot et al 2005, Koch and Newhauser 2005, Newhauser et
al 2005, Polf and Newhauser 2005, Polf et al 2005, Tayama et al 2006, Herault et al 2007,
Newhauser et al 2007a, 2007b, Zheng et al 2007a). The Monte Carlo code simulated the
entire trajectories of individual particles, beginning with protons entering the nozzle. The
particle trajectories were tracked through various beam shaping and collimating
components, nozzle shielding and the patient or phantom. Our double scattering nozzle
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(Hitachi Ltd; Probeat, Tarrytown, NY) was previously described in detail (Newhauser et al
2007a, Zheng et al 2007a). We simulated the treatment with a scanning nozzle just as we
would a double scattering treatment except that all neutrons emanating from the treatment
unit (external neutrons) were artificially terminated. Thus, only neutrons generated inside
the patient (internal neutrons) were present. This method ensured a fair comparison of the
proton nozzles by holding constant the absorbed dose distributions from primary proton
beam. Comparing the proportion of exposure from internal versus external neutrons is also
important for evaluating the shielding of a proton therapy treatment head (Fontenot et al
2008, Taddei et al 2008), particularly when static or dynamic collimators are used (Bues et
al 2005).
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To evaluate the exposures to a patient, we included an anthropomorphic phantom in the
simulation following the methods described by Fontenot et al (2008) and references therein.
Figure 1 shows the nozzle, phantom and particle fluences from individual proton treatment
fields. To facilitate comparison with results from the literature, we calculated a figure of
merit defined as the quotient of the effective dose, E, and the therapeutic absorbed dose, D,
at the isocenter. E is the weighted sum of equivalent doses to individual tissues (HT), where
we followed methods developed for radiation protection purposes (ICRP 1990, 2003). We
also calculated the radiation weighting factor (wR) for neutrons based on the Monte Carlo
simulations of the neutron spectral fluences. For the reader’s convenience, this calculation
approach is reviewed below.
The effective dose is given by
(1)

where the equivalent dose, HT, for each organ or tissue T is given by
(2)

In evaluating equation (1), we used tissue weighting factors, denoted by wT, from ICRP
Publication 60 (1990) (see table 1). There the mean absorbed dose to an organ or tissue (DT)
is given by a mass-weighted average over the entire organ, or
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(3)

However, in this work, we estimated DT from one or more subvolumes located within the
organ or tissue. For example, the mean dose to lung was taken as the average dose in two
spherical subvolumes (4.2 cm3 each) of lung tissue, one each in the central regions of the
right and left lungs. The use of subvolumes was used for simplicity and computational
efficiency. The radiation weighting factor in equation (2) is a function of neutron energy, En,
and may be calculated using a variety of empirical expressions, such as the most recent
recommendation from ICRP Publication 92 (2003), which was used in this work and is
given by
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The radiation weighting factor was designed to be conservative when applied to the general
population. However, the neutron radiation weighting factor for pediatric cancer patients
may be higher, although the available estimates are highly uncertain (NRC 2006). Therefore,
to test the impact of uncertainty in wR in our projected cancer risks, described below, we
compared results after multiplying the neutron radiation weighting factor in equation (4) by
scaling factors of 1, 2.5, 5, 20 and 35. Varying the scaling factor values allowed us to gauge
the sensitivity of our results to a possible systematic underestimation of the neutron radiation
weighting factors. While the choice of individual scaling factor values was somewhat
arbitrary, the interval of values was selected to bracket the range of plausible wR values.
2.2. Calculating the risk of developing a radiogenic second cancer
The risk of developing a second cancer was calculated for each organ or tissue using
(5)
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where RT is the absolute lifetime risk of secondary cancer, HT is the equivalent dose from
equation (2), MT is the coefficient of lifetime risk of fatal cancer per unit of radiation
exposure, and LT is the organ-specific lethality factor. The lethality factors convert the result
from risk of fatal cancer to risk of cancer that is fatal or non-fatal. The values of MT and LT
were taken from ICRP Publication 60 (1990) and are listed in table 1. These values were
selected for consistency with the methods of Miralbell et al (2002) and because they are
widely accepted.
The total lifetime risk to the patient for the development of a second cancer was calculated
as
(6)

and the yearly risk as

NIH-PA Author Manuscript

(7)

where the remaining lifetime tL is the life expectancy minus the age at treatment (in this
case, 76 − 3 = 73 yr).
To estimate R for a particular treatment modality, we combined the risks from the primary
beams, using data from Miralbell et al (2002), with risks from the stray radiation using data
from this work. Thus, we were able to explicitly partition the sources of risk in equation (6),
yielding
(8)
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To compare treatment modalities with one another, we calculated the relative risk according
to

NIH-PA Author Manuscript

(9)

where R0 was the value from equation (8) for the scanned-beam proton treatment.

3. Results
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The absorbed dose from stray radiation, radiation weighting factor and equivalent dose from
stray radiation are listed in table 2 for the major organs and tissues. These values were
simulated using the passively scattered proton therapy beam delivery method and include
only contributions from stray radiation, i.e. they do not include the in-field contribution from
the primary beam. The corresponding values for an idealized scanned-beam delivery are
listed in table 3. The equivalent dose for the complete three-field treatments varied from 2.5
mSv (to the gonads from the scanned-beam treatment) to approximately 443 mSv (to the
esophagus and thyroid from the passively scattered treatment). The values of equivalent
dose generally decreased with distance from the therapeutic field and were on average two
times higher from passive beams than from scanned beams. The radiation weighting factor
for neutrons, which was calculated inside various organs, was on average slightly larger and
more variable for the scanned treatment (mean wR = 9.0, interval of 5.9–10.9) than for
passively scattered treatment (mean wR = 8.0, interval of 6.7–9.2). The difference in wR
values from passively scattered treatments relative to the corresponding values from
scanned-beam treatments was due to changes in the shape of the neutron spectra due to
external neutrons. The effective dose from stray radiation was 187 mSv (E/D = 5.2 mSv
Gy−1) for the passive proton treatment versus 89 mSv (E/D = 2.5 mSv Gy−1) for the
scanned-beam treatment. The lifetime risk of second cancer due to stray radiation was 1.5%
for the passively scattered treatment versus 0.7% for the scanned-beam treatment. For stray
radiation from the passively scattered treatment, the largest proportions of the lifetime risk
were assumed by the skin (51% of total risk), thyroid (10%), colon (8%), lung (8%) and
stomach (8%). Together these organs were associated with 85% of the risk of second cancer
associated with all tissues and organs exposed to stray radiation. Risks posed by the scanned
proton treatments were quite similar, with the skin (47%), thyroid (17%), stomach (9%),
esophagus (7%) and lung (6%) together assuming 86% of the total risk of a second cancer
from stray radiation. Skin predominated the risk of second cancer from stray radiation
because the value of MT/LT in equation (5) for skin is larger (by factors of 10–350) than for
all other organs and tissues in table 1.
Next we describe the results of risk calculations that include both therapeutic and stray
radiation. Acomparison of the yearly cancer risks is summarized in table 4 for treatments
using conventional photon therapy (CRT), intensity-modulated photon therapy (IMRT),
passively scattered proton therapy (PSPT) and magnetically scanned intensity-modulated
proton therapy (IMPT). The proportions of risk associated with primary and secondary
radiation are listed separately, along with their sum (total risk). Using the radiation
weighting factors listed in tables 2 and 3 and calculating the relative risk with equation (9),
we found that the risk of second cancer associated with IMRT and CRT were, respectively,
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factors of 7 and 12 higher than with IMPT. The relative risk from passively scattered proton
therapy was only a factor of 1.2 larger than that from IMPT; that is, the risk following IMRT
and CRT were factors of 6 and 11, respectively, larger than following PSPT. The yearly
risks from IMPT and PSPT were both extremely small, at 0.060% and 0.070%, respectively.
The risks associated with both IMPT and PSPT were predominated by primary (in-field)
radiation associated with the therapeutic proton beams and not by stray neutron radiation. As
noted previously by Miralbell et al (2002), these small yearly risks can lead to substantial
lifetime risks for young patients with good prognoses for survival of their first cancer. For
example, the risk projections for the 3 year old boy (i.e. our reanalysis of data from
Miralbell et al that additionally took into account neutrons) revealed the lifetime risk of
second cancer incidence was approximately 4.4% following IMPT, 5.1% following PSPT,
31% following IMRT and 55% following CRT. To place the risks associated with proton
therapy in context, they are much larger than the risk of anesthesia-related (2.2 deaths per 10
000 procedures, or 0.02% incidence (Lagasse 2002)) and slightly larger than lifetime
occupational risks faced by healthy workers in various ‘safe’ industries, e.g. trade,
government, agriculture (0.2–1.8% lifetime incidence of fatal accident, assuming a 40 year
working career (NCRP 1993)).
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It is possible that the radiation weighting factors listed in tables 2 and 3, which were
developed for radiation protection of healthy individuals, were underestimated by equation
(4) when applied to a cancer patient. Similarly, the risk coefficients, tissue weighting factors
and lethality factors in table 1 may introduce a bias when applied to survivors of childhood
cancer. For example, young children who survive a first cancer may be more susceptible to
developing some second malignancies, such as cancer of the female breast (NRC 2006). To
test the sensitivity of our findings to systematic errors in this regard, we varied the wR value
for neutrons and recalculated the R and Rrel values. When the wR values were increased by a
factor of 2.5, the risk from stray neutrons and from primary radiation were approximately in
equal proportion for PSPT. Similarly, equipoise for IMPT was observed when the wR values
were increased by a factor of 5. However, even with these increases, the proton treatments
still had lower risks of second cancer incidence than either IMRT or CRT. On increasing wR
by a factor of 20, the second cancer risks associated with PSPT rose to approximately equal
those of IMRT. On increasing wR by a factor of 35, the risk from PSPT rose to
approximately equal that of CRT.
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4. Discussion
We used Monte Carlo simulations of stray neutron exposures to organs throughout the body
to estimate the risk of developing a second cancer in a patient receiving craniospinal proton
irradiation. In addition, we took into account exposures associated with the primary
radiation beam (i.e. the therapeutic field) from a previous investigation. Our results confirm
that proton therapy offers substantially lower second cancer risks than 6 MV photon
radiotherapies, even when the risk associated with neutrons is taken into account.
Our findings are qualitatively and quantitatively similar to those of Miralbell et al (2002)
and Mu et al (2005). Those studies suggested that proton therapy offered lower risk for the
development of second cancer, although Mirabell et al did not account for the contribution
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of neutron radiation. Mu et al estimated neutron effective dose at 47 mSv for a 23.4 Gy
treatment with IMPT only, and these were based on values from the literature. Our estimates
of effective dose from neutrons were 89 mSv for IMPT and 187 mSv for PSPT, which was
due in part to our larger (36 Gy) treatment dose. Our risk analysis, which did take neutrons
into account, revealed that the second cancer risks associated with the passively scattered
and scanned proton treatments were predominated by contributions from the primary beams;
the neutron exposures comprise a much smaller proportion of the total risk. For example, we
estimated that the second cancer risk from IMRT was 7.1 times larger than from IMPT,
which is not substantially different from the factor of 8.6 reported by Miralbell et al (2002).
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One of the major clinical implications of this work is that the cancer risks associated with
proton therapy are predominated by primary proton radiation, not stray neutron radiation. In
particular, our results shed some light on the troublingly large uncertainties in the assumed
neutron radiation weighting factor. Hall (2006) recently cautioned that pediatric patients
receiving passively scattered proton therapy might be at excessive risk of developing second
cancers if the true neutron weighting factor has been substantially underestimated (in this
study, we calculated typical wR values of approximately 8). Our analysis suggests, however,
that proton therapy has a lower associated risk of second cancer when compared with IMRT
or CRT. This finding holds if wR ≤ 50 for the neutron exposures, which contains the interval
of plausible values.
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The interval of ‘plausible’ neutron radiation weighting factors is itself somewhat
controversial, and because of its central importance to this investigation, some discussion is
warranted. The Biological Effects of Ionizing Radiation (BEIR) committee of the National
Research Council recently reviewed experimental data on the relative biological
effectiveness (RBE) of neutrons for the induction of cancer (NRC 2006). This quantity is
closely related to the radiation weighting factor for neutrons in equation (4). For the
induction of solid tumors they concluded that, for the purpose of risk estimation, the relevant
RBE data from rodent experiments were in the interval of 20–50, whereas lower neutron
RBE values were relevant for leukemia. In their analysis of atomic bomb survivors, the
BEIR committee adopted a much lower, constant value of wR = 10 and stated that they
rejected a suggestion that ‘a weighting factor of roughly 30 for the neutron-absorbed dose
might be a better choice than 10’ (NRC 2006). However, the exact choice remains
controversial and the importance of this fact cannot be overstated. For example, Kellerer et
al (2006) recently analyzed the data for atomic bomb survivors and deduced that the 95%
confidence interval of neutron RBE values was 25–400. They emphasized that ‘the
inferences are at present tentative’ and that their analysis ‘included no separate category for
neutron dose’. Because the true RBE values for neutrons will not be known with certainty
anytime soon, we adopted the recommendation of the BEIR committee, which is consistent
with the preponderance of evidence in the literature, namely, that the true value of the
neutron RBE for carcinogenesis is 50 or less, with uncertainties that are large and difficult to
estimate. Even with such large uncertainties in the neutron weighting factor, it is still
possible to make meaningful comparisons of the second cancer risks from proton therapy
versus photon therapy.
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To demonstrate this, consider the following example. We mathematically solved for the
value of wR that yielded equal risks for IMRT and PSPT. This solution yielded wR = 152, or
approximately 19 times higher than the value we used. Similarly, the mathematical solution
of equal risks for IMRT and IMPT yielded wR = 333, or approximately 37 times higher than
the value we used. These wR values are well beyond the interval of plausible values. Thus,
based on the calculations of the pediatric treatment considered here, one may reasonably
conclude that proton therapy offers a lower risk of second cancer regardless of the value
used for the neutron weighting factor or its uncertainty; the same conclusion holds for all
plausible values of wR.
That being said, we wish to underscore the important role of other, smaller but not negligible
sources of uncertainty in risk projections for proton therapy patients. For example, the
neutron-absorbed dose values are dependent on many variables, including the beam range,
field size, air gap and distance from the treatment unit (Zheng et al 2007a, 2007b, 2008).
Recent studies have also shown that the dosimetric results depend to some extent on the
method of calculation (Fontenot et al 2008, Zheng et al 2008).
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While this study had several features that might be viewed as limitations, we are confident
of our conclusions. First, the phantom used for neutron dose calculations was selected for
computational efficiency; it was substantially larger than the 3 year old patient for which the
primary radiation exposures were calculated. However, this was not a serious limitation
because the out-of-field neutron-absorbed dose and radiation weighting factor generally did
not vary strongly with depth or position within the phantom. Furthermore, the use of an
adult phantom necessitated larger proton beam ranges, SOBP widths and field sizes than
would have been required for the patient, which would result in an overestimation of the
equivalent dose from neutrons (Zheng et al 2007a, 2007b, 2008). Because each of these
factors tended to increase the neutron exposures, the true risks associated with the proton
treatments may be somewhat lower than our estimates. Lower neutron-related risks would
not change the major findings of this work; rather, they would reinforce them.
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Finally, Hall (2007) recently posed the following important question. ‘Does it make any
sense to spend over $100 million on a proton facility, with the aim to reduce doses to normal
tissues, and then to bathe the patient with a total body dose of neutrons, the RBE of which is
poorly known, when the technology to avoid it is available and already in use elsewhere?’ In
the same article, Hall opined that ‘protons are a major step forward for radiotherapy, but
neutrons are bad news and must be minimized by the use of spot scanning techniques’.
While we agree that proton therapy represents a major advance, we differ with Hall’s other
key statements and inferences. First, low-cost proton therapy systems (<$15 million US) are
on the horizon, and in our view, even the high-capacity $100 million facilities represent an
excellent value when one considers the achievable savings in total cost to society through
reductions in treatment-related morbidity and mortality. For example, Lundkvist et al (2005)
reported a cost/benefit analysis in which they found that proton therapy for childhood
medulloblastoma provided lower total cost and better outcomes than conventional radiation
therapy. Second, our results revealed that proton therapies carry lower risks of second
cancer, even with large and poorly known values of neutron RBE for carcinogenesis, as
discussed above. Third, in the case we examined, using spot scanning instead of passive
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scattering reduced the second cancer risk by only about 20%, after taking into account the
contributions to risk from the therapeutic beam and stray radiation. This reduction would
come at a cost; there are potentially serious yet poorly understood risks associated with the
dosimetric hot and cold spots caused by the interplay of beam and organ motion (Grozinger
et al 2006). In fact, given that fewer than 300 patients have been treated with scanned proton
beams (Timmermann et al 2007) versus more than 40 000 (Sisterson 2005) with scattered
proton beams, many of the recently claimed benefits from scanned-beam treatments seem
overly optimistic and premature.
Given the complexities and uncertainties associated with second-cancer risk assessments,
additional studies are needed to test whether the same conclusions will hold for patients of
other ages and anatomical statures. At present, the available literature on stray radiation
exposures for proton therapy is still extremely limited compared with that for photon
therapy. For these reasons, we caution against drawing sweeping conclusions about proton
radiotherapy until more information becomes available. In our laboratory, additional studies
are now under way to address some of these issues, with an emphasis on improving the
accuracy of absorbed doses from the primary and stray radiation fields.
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Figure 1.

Monte Carlo simulation of particle fluences for the three craniospinal treatment fields. The
upper plots represent the logarithm of the proton fluence, including primary protons and
secondary protons generated via (n, xp) reactions in the treatment unit and in the phantom.
The corresponding lower plots represent the logarithm of neutron fluence, including
neutrons generated internally and externally to the phantom. Note that the fluence in each
plot was scaled to maximize the visibility of the shape of the distributions, not their
magnitude. (A), (B) Cranial field. (C), (D) Superior spinal field. (E), (F) Inferior spinal field.
(This figure is in colour only in the electronic version)
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Coefficient of lifetime risk of fatal second cancer (MT), tissue weighting factor (wT) and lethality fraction (LT)
from ICRP Publication 60 (1990).
Tumor site

MT(%/Sv)

wT

LT

NIH-PA Author Manuscript

Gonads

0.10

0.2

0.70

Bone marrow (red)

0.50

0.12

0.99

Colon

0.85

0.12

0.55

Lung

0.85

0.12

0.95

Stomach

1.10

0.12

0.90

Bladder

0.30

0.05

0.50

Breast

0.20

0.05

0.50

Liver

0.15

0.05

0.95

Esophagus

0.30

0.05

0.95

Thyroid

0.08

0.05

0.10

Skin

0.02

0.01

0.002

Bone surface

0.05

0.01

0.70

Remainder

0.50

0.05

0.71
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5.80 × 10−4
10−4

1.86 ×
4.45 ×
3.07 ×

1.45 × 10−4
10−5
10−5
10−4

9.36 ×

7.06 ×

1.55 × 10−4
10−3

1.08 ×
1.08 ×

10−4

1.56 ×
8.82 × 10−5
10−4

3.52 ×

Bladder

Breast

Liver

2.76 ×

1.06 ×

10−4

Remainder

2.76 ×

10−4

1.06 ×

10−4

1.06 × 10−4

Skin

Bone surface

2.76 × 10−4

2.00 ×

Thyroid

10−4

10−3

2.00 ×

Esophagus

10−4

10−5

8.94 ×

Stomach

10−5

Lung

2.76 ×

10−5

Colon

10−4

10−4

1.06 ×

3.71 × 10−5

2.30 × 10−5

Gonads

Bone marrow (red)

Sup spine

Cranial

Organ

DT/D (Gy/Gy)

10−4

10−4

10−4

10−4

2.27 ×

2.27 ×
10−4

10−4

2.27 × 10−4

1.20 ×

1.20 ×

10−4

4.04 × 10−4

2.44 ×

1.05 ×

4.04 ×

10−4

2.40 × 10−4

3.72 ×

2.27 ×

10−4

5.97 × 10−5

Inf spine

7.8

7.8

7.8

7.9

7.9

8.0

8.1

7.2

8.0

8.0

7.8

7.8

6.7

Cranial

7.9

7.9

7.9

9.1

9.1

8.2

8.4

7.2

8.3

8.5

8.1

7.9

6.7

Sup spline

wR(Sv/Gy)

8.1

8.1

8.1

7.5

7.5

9.1

8.3

7.8

9.1

8.1

9.2

8.1

7.2

Inf spine

10−4

10−3

10−4

10−3

8.27 ×

8.27 ×

10−4

10−4

8.27 × 10−4

1.58 ×

1.58 ×

10−3

7.06 × 10−4

1.26 ×

2.53 ×

7.15 ×

10−4

1.16 × 10−3

5.51 ×

8.27 ×

10−4

1.54 × 10−4

Cranial

10−4

10−3

10−4

10−3

2.18 ×

2.18 ×

10−3

10−3

2.18 × 10−3

9.83 ×

9.83 ×

10−3

1.27 × 10−3

2.58 ×

3.20 ×

1.54 ×

10−3

4.93 × 10−3

7.58 ×

2.18 ×

10−3

2.49 × 10−4

Sup spine

HT/D (Sv/Gy)

10−3

10−3

10−4

10−4

1.84 ×

1.84 ×

10−3

10−3

1.84 × 10−3

9.00 ×

9.00 ×

10−4

3.68 × 10−3

2.03 ×

8.19 ×

3.68 ×

10−3

1.94 × 10−3

3.42 ×

1.84 ×

10−3

4.30 × 10−4

Inf spine

0.12

0.01

1.74

0.35

0.14

0.03

0.08

0.03

0.26

0.26

0.26

0.09

0.00

RT
(%)

3.6

0.4

51.4

10.4

4.1

0.9

2.5

0.9

7.7

7.6

7.8

2.6

0.1

RT/R
(%)

for the cranial, superior spinal and inferior spinal treatment fields. These data were simulated for a commercially available treatment unit at The
University of Texas M D Anderson Cancer Center (Newhauser et al 2007a).

corresponding percentage of risk in all tissues and organs (RT/R). The values of absorbed dose and radiation weighting factor values are listed separately

DT), lifetime risk of fatal or non-fatal second cancer (RT) from stray radiation corresponding to the entire three-field, 36 Gy treatment and the

Predicted exposures of stray radiation from craniospinal irradiation using passively scattered proton beams, including absorbed dose of stray radiation per
therapeutic absorbed dose (DT/D), radiation weighting factor (wR) for neutrons, equivalent dose from stray radiation per therapeutic absorbed dose (HT/
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2.16 × 10−4
10−5

6.69 ×
1.97 ×
1.53 ×

3.43 × 10−5
10−1
10−7
10−5

5.12 ×

1.65 ×

5.96 × 10−5
10−4

7.73 ×
7.73 ×

10−5

1.01 ×
3.57 × 10−6
10−5

5.46 ×

Bladder

Breast

Liver

1.26 ×

1.66 ×

Remainder

1.26 ×

10−5

1.66 ×

10−4

10−5

Bone Surface

1.26 × 10−4

5.22 ×
1.66 × 10−5

Skin

10−4

10−4

5.22 ×

Esophagus

Thyroid

10−4

10−6

5.38 ×

Stomach

10−6

Lung

1.26 ×

10−6

1.66 ×

10−4

10−5

Colon

1.94 × 10−6

7.12 × 10−7

Gonads

Bone marrow (red)

Sup spine

Cranial

Organ

DT/D (Gy/Gy)

10−4

10−5

10−5

10−5

7.66 ×

7.66 ×
10−5

10−5

7.66 × 10−5

3.37 ×

3.37 ×

10−5

5.96 × 10−4

8.97 ×

2.15 ×

2.23 ×

10−4

4.79 × 10−5

1.19 ×

7.66 ×

10−5

6.14 × 10−6

Inf spine

7.6

7.6

7.6

9.3

9.3

7.9

8.6

7.1

8.1

8.5

7.1

7.6

5.9

Cranial

9.1

9.1

9.1

10.5

10.5

10.3

9.6

7.8

10.2

10.4

9.3

9.1

7.3

Sup spine

wR(Sv/Gy)

9.5

9.5

9.5

9.4

9.4

10.8

9.4

9.5

10.7

10.1

10.9

9.5

8.4

Inf spine

10−5

10−5

10−6

10−4

1.26 ×

1.26 ×

10−4

10−4

1.26 × 10−4

4.88 ×

4.88 ×

10−4

2.82 × 10−5

8.68 ×

3.90 ×

4.34 ×

10−5

2.92 × 10−4

1.18 ×

1.26 ×

10−4

4.18 × 10−6

Cranial

10−5

10−3

10−5

10−3

1.15 ×

1.15 ×

10−3

10−3

1.15 × 10−3

8.16 ×

8.16 ×

10−3

6.14 × 10−4

1.47 ×

1.53 ×

6.81 ×

10−4

2.25 × 10−3

4.79 ×

1.15 ×

10−3

1.41 × 10−5

Sup spine

HT/D (Sv/Gy]

10−3

10−4

10−4

10−4

7.28 ×

7.28

10−4

10−4

7.28 × 10−4

3.16 ×

3.16

10−4

2.12 × 10−3

8.46 ×

2.05 ×

2.4 ×

10−3

4.84 × 10−4

1.30 ×

7.28 ×

10−4

5.16 × 10−5

Inf spine

0.05

0.01

0.72

0.27

0.11

0.02

0.03

0.00

0.14

0.10

0.08

0.04

0.0004

RT
(%)

3.3

0.3

46.3

17.3

6.8

1.0

2.2

0.3

8.8

6.3

4.9

2.3

0.02

RT/R
(%)

superior spinal and inferior spinal treatment fields. The dosimetric data were simulated for an idealized scanned-beam proton therapy unit from which no
leakage radiation emanated, i.e. only stray radiation generated internally to the patient was considered.

percentage of risk in all tissues and organs (RT/R). The values of absorbed dose and radiation weighting factor values are listed separately for the cranial,

lifetime risk of fatal or non-fatal second cancer (RT) from stray radiation corresponding to the entire three-field, 36 Gy treatment, and the corresponding

Predicted exposures of stray radiation from a craniospinal irradiation using scanned proton beams, including absorbed dose of stray radiation per
therapeutic absorbed dose (DT/D), radiation weighting factor (wR) for neutrons, equivalent dose of stray radiation per therapeutic absorbed dose (HT/DT),
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0.15
0.0
0.07
0.18
0.03
0.07
0.75

Breast

Lung

Thyroid

Bone and connective tissue

Leukemia

All

All

IMPT

PSPT

IMPT

0.43

0.05

0.02

0.06

0.07

0.0

0.07

0.11

0.05

0.03

0.01

0.0

0.01

0.0

0.0

0.0

0.0200

0.0012

0.0002

0.0049

0.0035

0.0012

0.0036

0.0055

0.0105

0.0005

0.0001

0.0037

0.0013

0.0005

0.0010

0.0033

31.4

3.7

1.5

0.76

5.1

0.070

0.031

0.010

0.005

0.014

0.001

0.004

0.005

PSPT

4.4

0.060

0.030

0.010

0.004

0.011

0.000

0.001

0.003

IMPT

Risk associated
with primary and
secondary radiation

12.4

7.1

0.8

0.3

0.2

1.2

1.0

Ratio of lifetime risk of second cancer from various irradiation to that from IMPT, Rrel

54.8

Lifetime risk of second cancer, R, in percent

0.15

Colon

All

IMRT

Risk associated
with secondary
radiation

Annual risk of second cancer, Ry, (%/yr)

CRT

Stomach and esophagus

Tumor site

Risk associated
with primary
radiation

Comparison of organ doses and risks of second cancer from various treatment modalities, including conventional photon therapy (CRT), intensitymodulated photon therapy (IMRT), passively scattered proton therapy (PSPT) and magnetically scanned proton therapy (IMPT). The values for CRT,
IMRT and the primary component of IMPT were taken from Miralbell et al (2002). The stray radiation contributions to PSPT and IMPT treatments were
simulated using a Monte Carlo model. The primary contribution for PSPT was approximated as the primary value for IMPT. The values in the bottom
row represent the relative risk of second cancer incidence, where each value was normalized to the result for IMPT.
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